Santhera Pharmaceuticals (SIX Swiss Exchange: SANN, OTC: SPHDF) is a clinical stage specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. The Company’s lead candidate is Raxone/Catena as a treatment for patients with Duchenne muscular dystrophy (DMD), Leber’s hereditary optic neuropathy (LHON), and primary progressive multiple sclerosis (PPMS), all areas of high unmet medical need with no FDA-approved therapies. Santhera is the only company in the DMD space to successfully complete a Phase III trial. The Company recently submitted an MAA for European approval to treat LHON and is in discussions with the FDA on a pathway for US regulatory approval.

Read More